- Home
- OPTH vs CRVO Comparison
OPTH vs CRVO Comparison
Compare OPTH & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPTH | CRVO |
|---|---|---|
| Founded | N/A | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 25.9M |
| IPO Year | 2024 | 2011 |
Fundamental Metrics
Financial Performance| Metric | OPTH | CRVO |
|---|---|---|
| Price | $4.75 | $2.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 29.1K | ★ 276.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.00 | $2.13 |
| 52 Week High | $5.45 | $10.00 |
Technical Indicators
Market Signals| Indicator | OPTH | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 40.89 |
| Support Level | $4.44 | $2.47 |
| Resistance Level | $5.00 | $3.20 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 16.20 | 26.68 |
Price Performance
Historical ComparisonAbout OPTH Optimi Health Corp. Common Shares
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.